Document:

Exhibit 10.2

 

Xenetic
Biosciences, Inc.

Stock Option Grant Notice

(Inducement
Award)

 

Xenetic Biosciences, Inc. (the “Company”),
pursuant to the attached Nonstatutory Stock Option Agreement (the “Option Agreement”), hereby grants
to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. The option is subject
to all of the terms and conditions as set forth in this notice, the Option Agreement, and the Notice of Exercise, all of which
are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the
Option Agreement will have the same definitions as in the Option Agreement. If there is any conflict between the terms in this
notice and the Option Agreement, the terms of the Option Agreement will control. This option is intended to be an award described
in NASDAQ Listing Rule 5635(c)(4) and is being made to the Optionholder as an inducement material to the Optionholder’s entering
into employment with the Company.

 

	Optionholder:	
        James
        F. Parslow

	Date of Grant:	
        April
        3, 2017

	Vesting Commencement Date:	
        Date
of Grant

	Number of Shares Subject to Option:	
        175,000

	Exercise Price (Per Share):	
        $4.57

	Total Exercise Price:	
        $799,750

	Expiration Date:	
        April
        3, 2027

 

	Type of Grant:	 	Nonstatutory Stock
Option
	 	 	 
	Exercise Schedule:	 	Same as Vesting Schedule
	 	 	 
	Vesting Schedule:	 	One-third
(1/3) of the shares subject to this option vest on each of the first three anniversaries of Vesting Commencement Date, subject
to Optionholder’s Continuous Service as of each such date. In the event of a Change in Control, any then unvested and outstanding
shares subject to this option shall vest effective immediately prior to, but subject to the occurrence of such Change in Control
and subject to the Optionholder’s Continuous Service through such Change in Control.
	 	 	 
	Payment: 	 	By one or a combination of the following
items (described in the Option Agreement):
	 	 	 
	 	 	x     By cash, check, bank draft or money order payable to the Company
	 	 	x     Pursuant
to a Regulation T Program if the shares are publicly traded
	 	 	x     By
delivery of already-owned shares if the shares are publicly traded

 

Additional Terms/Acknowledgements:
Optionholder acknowledges receipt of, and understands and agrees to, this Stock Option Grant Notice and the Option Agreement. Optionholder
acknowledges and agrees that this Stock Option Grant Notice and the Option Agreement may not be modified, amended or revised except
as provided in the Option Agreement. Optionholder further acknowledges that as of the Date of Grant, this Stock Option Grant Notice
and the Option Agreement set forth the entire understanding between Optionholder and the Company regarding this option award and
supersede all prior oral and written agreements, promises and/or representations on that subject with the exception of (i) options
previously granted and delivered to Optionholder, (ii) any compensation recovery policy that is adopted by the Company or is otherwise
required by applicable law and (iii) any written employment or severance arrangement that would provide for vesting acceleration
of this option upon the terms and conditions set forth therein.

 

 

 

 

    	 	1	 

     

    

 

By accepting this option, Optionholder
consents to receive such documents by electronic delivery and to participate through an on-line or electronic system established
and maintained by the Company or another third party designated by the Company.

 

 

	 	 	 
	Xenetic Biosciences, Inc. 	 	Optionholder: 
	 	 	 
	 	 	 
	 	 	 
	By: /s/ Jeffrey F. Eisenberg                     	 	         /s/ James F. Parslow                         
	                      Signature	 	                        Signature
	 	 	 
	Title: Chief Operating Officer	 	Date: April 3, 2017
	Date: April 3, 2017	 	 

 

Attachments:
Option Agreement and Notice of Exercise

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	2	 

     

    

 

Attachment I

 

Xenetic
Biosciences, Inc.

Nonstatutory Stock Option Agreement

 

Pursuant to your Stock
Option Grant Notice (“Grant Notice”) and this Nonstatutory Stock Option Agreement (the “Option
Agreement”), Xenetic Biosciences, Inc. (the “Company”) has granted you a nonstatutory
stock option to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise
price indicated in your Grant Notice (your “option”). Your option is granted to you effective as of the
date of grant set forth in the Grant Notice (the “Date of Grant”). The option is granted in compliance
with NASDAQ Listing Rule 5635(c)(4) as a material inducement to you entering into employment with the Company.

 

The details of your
option, in addition to those set forth in the Grant Notice, are as follows:

 

1.                 
Vesting. Your option
will vest as provided in your Grant Notice. Vesting will cease upon the termination of your Continuous Service.

 

2.                 
Number of Shares and Exercise Price. The
number of shares of Common Stock subject to your option and your exercise price per share in your Grant Notice will be adjusted
for Capitalization Adjustments. 

 

3.                 
Exercise Restriction for Non-Exempt Employees.
If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938,
as amended (that is, a “Non-Exempt Employee”), you may not exercise your option until you have completed
at least six (6) months of Continuous Service measured from the Date of Grant, even if you have already been an employee for more
than six (6) months. Consistent with the provisions of the Worker Economic Opportunity Act, you may exercise your option as to
any vested portion prior to such six (6) month anniversary in the case of (i) your death or Disability, (ii) a Change in Control
in which your option is not assumed, continued or substituted, or (iii) your termination of Continuous Service on your “retirement”
(as defined in the Company’s benefit plans). 

 

4.                 
Method of Payment. You
must pay the full amount of the exercise price for the shares you wish to exercise. You may pay the exercise price in cash or by
check, bank draft or money order payable to the Company or in any other manner permitted by your Grant Notice, which
may include one or more of the following:

 

(a)              
Provided that at the time of exercise the Common Stock is publicly traded, pursuant to
a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock,
results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate
exercise price to the Company from the sales proceeds. This manner of payment is also known as a “broker-assisted exercise”,
“same day sale”, or “sell to cover”.

 

(b)             
Provided that at the time of exercise the Common Stock is publicly traded, by delivery
to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear
of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise. “Delivery”
for these purposes, in the sole discretion of the Company at the time you exercise your option, will include delivery to the Company
of your attestation of ownership of such shares of Common Stock in a form approved by the Company. You may not exercise your option
by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting
the redemption of the Company’s stock.

 

 

 

 

    	 	3	 

     

    

 

5.                 
Whole Shares. You
may exercise your option only for whole shares of Common Stock.

 

6.                 
Securities Law Compliance. In
no event may you exercise your option unless the shares of Common Stock issuable upon exercise are then registered under the Securities
Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the
registration requirements of the Securities Act. The exercise of your option also must comply with all other applicable laws and
regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not
be in material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas.
Reg. 1.401(k)-1(d)(3), if applicable).

 

7.                 
Term. You may not
exercise your option before the Date of Grant or after the expiration of your option’s term. The term of your option expires
upon the earliest of the following:

 

(a)              
immediately upon the termination of your Continuous Service for Cause;

 

(b)             
three (3) months after the termination of your Continuous Service for any reason other
than Cause, your Disability or your death (except as otherwise provided in Section 7(d) below); provided, however, that
if during any part of such three (3) month period your option is not exercisable solely because of the condition set forth in the
section above relating to “Securities Law Compliance,” your option will not expire until the earlier of the Expiration
Date or until it has been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service;

 

(c)              
twelve (12) months after the termination of your Continuous Service due to your Disability
(except as otherwise provided in Section 7(d)) below;

 

(d)             
eighteen (18) months after your death if you die either during your Continuous Service
or within three (3) months after your Continuous Service terminates for any reason other than Cause;

 

(e)              
the Expiration Date indicated in your Grant Notice; or

 

(f)               
the day before the tenth (10th) anniversary of the Date of Grant.

 

8.                 
Exercise.

 

(a)              
You may exercise the vested portion of your option (and the unvested portion of your option
if your Grant Notice so permits) during its term by (i) delivering a Notice of Exercise (in a form designated by the Company) or
completing such other documents and/or procedures designated by the Company for exercise and (ii) paying the exercise price and
any applicable withholding taxes to the Company’s Secretary, stock plan administrator, or such other person as the Company
may designate, together with such additional documents as the Company may then require.

 

(b)             
By exercising your option you agree that, as a condition to any exercise of your option,
the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding
obligation of the Company arising by reason of (i) the exercise of your option, (ii) the lapse of any substantial risk of forfeiture
to which the shares of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired
upon such exercise.

 

 

 

 

    	 	4	 

     

    

 

9.                 
Transferability. Except
as otherwise provided in this Section 9, your option is not transferable, except by will or by the laws of descent and distribution,
and is exercisable during your life only by you.

 

(a)              
Certain Trusts. Upon receiving written permission
from the Board or its duly authorized designee, you may transfer your option to a trust if you are considered to be the sole beneficial
owner (determined under Section 671 of the Code and applicable state law) while your option is held in the trust. You and the trustee
must enter into transfer and other agreements required by the Company. 

 

(b)             
Domestic Relations Orders. Upon receiving
written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into
transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic relations
order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2)
that contains the information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed terms
of any division of your option with the Company prior to finalizing the domestic relations order or marital settlement agreement
to help ensure the required information is contained within the domestic relations order or marital settlement agreement.

 

(c)              
Beneficiary Designation. Upon receiving written
permission from the Board or its duly authorized designee, you may, by delivering written notice to the Company, in a form approved
by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death,
will thereafter be entitled to exercise your option and receive the Common Stock or other consideration resulting from such exercise.
In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise your option and
receive, on behalf of your estate, the Common Stock or other consideration resulting from such exercise.

 

10.             
Option not a Service Contract. Your
option is not an employment or service contract, and nothing in your option will be deemed to create in any way whatsoever any
obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue
your employment. In addition, nothing in your option will obligate the Company or an Affiliate, their respective stockholders,
boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the
Company or an Affiliate.

 

11.             
Withholding Obligations.

 

(a)              
At the time you exercise your option, in whole or in part, and at any time thereafter
as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise
agree to make adequate provision for (including by means of a “same day sale” pursuant to a program developed under
Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy
the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection
with the exercise of your option. 

 

 

 

 

 

 

 

 

    	 	5	 

     

    

 

(b)             
Upon your request and subject to approval by the Company, and compliance with any applicable
legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon
the exercise of your option a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of
the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be
necessary to avoid classification of your option as a liability for financial accounting purposes). If the date of determination
of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant
to the preceding sentence shall not be permitted unless you make a proper and timely election under Section 83(b) of the Code,
covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is
otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your option.
Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common
Stock determined as of the date of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences
to you arising in connection with such share withholding procedure shall be your sole responsibility.

 

(c)              
You may not exercise your option unless the tax withholding obligations of the Company
and/or any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option
is vested, and the Company will have no obligation to issue a certificate for such shares of Common Stock or release such shares
of Common Stock from any escrow provided for herein, if applicable, unless such obligations are satisfied.

 

12.             
Tax Consequences.
You hereby agree that the Company does not have a duty to design or administer the Option Agreement or its other compensation programs
in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its officers, Directors,
Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge
that your option is exempt from Section 409A of the Code only if the exercise price per share specified in the Grant Notice is
at least equal to the “fair market value” per share of the Common Stock on the Date of Grant and there is no other
impermissible deferral of compensation associated with your option.

 

13.             
Notices. Any notices
provided for in your option will be given in writing (including electronically) and will be deemed effectively given upon receipt
or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United States mail, postage
prepaid, addressed to you at the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver
any documents related to your option by electronic means. By accepting your option, you consent to receive such documents by electronic
delivery and to participate through an on-line or electronic system established and maintained by the Company or another third
party designated by the Company.

 

14.             
Administration.

 

(a)              
Administration by Board. The Board will administer
your option. The Board may delegate administration of your option to a Committee or Committees, as provided in Section 14(c).

 

(b)             
Powers of Board. The Board will have the power,
subject to, and within the limitations of, the express provisions of your option:

 

(i)                
To construe and interpret your option, and to establish, amend and revoke rules and regulations
for administration of your option. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency
in the Grant Notice, Option Agreement and Notice of Exercise, in a manner and to the extent it will deem necessary or expedient
to make your option fully effective.

 

 

 

 

 

 

 

 

    	 	6	 

     

    

 

(ii)             
To settle all controversies regarding your option.

 

(iii)           
To accelerate, in whole or in part, the time at which your option may be exercised or
vest (or at which cash or shares of Common Stock may be issued). 

 

(iv)            
To amend the terms of your option, including, but not limited to, amendments to provide
terms more favorable to you than previously provided in the Grant Notice, Option Agreement or Notice of Exercise; provided however,
that your rights under the Grant Notice, Option Agreement and Notice of Exercise will not be impaired by any such amendment unless
the Company obtains your written consent. Notwithstanding the foregoing, (1) your rights will not be deemed to have been impaired
by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially
impair your rights, and (2) subject to the limitations of applicable law, if any, the Board may amend the terms of your option
without your consent to clarify the manner of exemption from, or to bring your option into compliance with, Section 409A of the
Code; or to comply with other applicable laws.

 

(v)              
Generally, to exercise such powers and to perform such acts as the Board deems necessary
or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Grant Notice,
Option Agreement or Notice of Exercise. 

 

(c)              
Delegation to Committee. The Board may delegate
some or all of the administration of your option to a Committee or Committees. If administration of your option is delegated to
a Committee, the Committee will have, in connection with the administration of your option, the powers theretofore possessed by
the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of
the administrative powers the Committee is authorized to exercise (and references in your Option Agreement to the Board will thereafter
be to the Committee or subcommittee). Any delegation of administrative powers will be reflected in resolutions, not inconsistent
with the provisions of your option, adopted from time to time by the Board or Committee (as applicable). The Committee may, at
any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee. The Board may retain
the authority to concurrently administer your option with the Committee and may, at any time, revest in the Board some or all of
the powers previously delegated.

 

(d)             
Effect of Board’s Decision. All determinations,
interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final,
binding and conclusive on all persons.

 

15.             
Adjustments upon Changes in Common Stock; Other Corporate
Events.

 

(a)              
Capitalization Adjustments. In the event of
a Capitalization Adjustment, the Board will appropriately and proportionately adjust the class(es) and maximum number of securities
that may be issued pursuant to the exercise of your option and the exercise price per-share of your option, and its determination
will be final, binding and conclusive.

 

(b)             
Change in Control. The following provisions
will apply to your option in the event of a Change in Control unless otherwise provided in any other written agreement between
the Company or any Affiliate and you. In the event of a Change in Control, then, notwithstanding any other provision of the Option
Agreement, the Board may take one or more of the following actions with respect to your option, contingent upon the closing or
completion of the Change in Control:

 

 

 

 

 

 

 

 

    	 	7	 

     

    

 

(i)                
arrange for the surviving corporation or acquiring corporation (or the surviving or acquiring
corporation’s parent company) to assume or continue your option or to substitute a similar stock award for your option (including,
but not limited to, an award to acquire the same consideration paid to the stockholders of the Company pursuant to the Change in
Control);

 

(ii)             
arrange for the assignment of any reacquisition or repurchase rights held by the Company
in respect of Common Stock issued pursuant to your option to the surviving corporation or acquiring corporation (or the surviving
or acquiring corporation’s parent company);

 

(iii)           
accelerate the vesting, in whole or in part, of your option (and, if applicable, the time
at which your option may be exercised) to a date prior to the effective time of such Change in Control as the Board determines
(or, if the Board does not determine such a date, to the date that is five (5) days prior to the effective date of the
Change in Control), with such option terminating if not exercised (if applicable) at or prior to the effective time of the Change
in Control; provided, however, that the Board may require you to complete and deliver to the Company a notice of exercise before
the effective date of a Change in Control, which exercise is contingent upon the effectiveness of such Change in Control;

 

(iv)            
arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights
held by the Company with respect to your option; 

 

(v)              
cancel or arrange for the cancellation of your option, to the extent not vested or not
exercised prior to the effective time of the Change in Control, in exchange for such cash consideration, if any, as the Board,
in its sole discretion, may consider appropriate; and

 

(vi)            
make a payment, in such form as may be determined by the Board equal to the excess, if
any, of (A) the value of the property you would have received upon the exercise of your option immediately prior to the effective
time of the Change in Control, over (B) any exercise price payable by such holder in connection with such exercise. For clarity,
this payment may be zero ($0) if the value of the property is equal to or less than the exercise price. Payments under this provision
may be delayed to the same extent that payment of consideration to the holders of the Company’s Common Stock in connection
with the Change in Control is delayed as a result of escrows, earn outs, holdbacks or any other contingencies.

 

The Board need not
take the same action or actions with respect to all portions of your option or with respect to all equity awards granted to you
and/or other service providers of the Company. Your option may be subject to additional acceleration of vesting and exercisability
as may be provided in the Grant Notice or as may be provided in any other written agreement between the Company or any Affiliate
and you, but in the absence of such provision, no such acceleration will occur.

 

(c)              
Dissolution of Liquidation. In the event of
a dissolution or liquidation of the Company, your option will terminate immediately prior to the completion of such dissolution
or liquidation, and the shares of Common Stock subject to the Company’s repurchase rights or subject to a forfeiture condition
may be repurchased or reacquired by the Company notwithstanding the fact that you may be providing Continuous Service, provided,
however, that the Board may, in its sole discretion, cause your option to become fully vested, exercisable and/or no longer
subject to repurchase or forfeiture (to the extent your option has not previously expired or terminated) before the dissolution
or liquidation is completed but contingent on its completion. 

 

 

 

 

 

 

 

 

    	 	8	 

     

    

 

16.             
Miscellaneous.

 

(a)              
Use of Proceeds from Sales of Common Stock. Proceeds
from the sale of shares of Common Stock pursuant to your options will constitute general funds of the Company.

 

(b)             
Corporate Action Constituting Grant of Options.
Corporate action constituting a grant by the Company of your option will be deemed completed as of the date of such corporate action,
unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing your option is communicated
to, or actually received or accepted by, you. In the event that the corporate records (e.g., Board consents, resolutions or minutes)
documenting the corporate action constituting the grant contain terms (e.g., exercise price, vesting schedule or number of shares)
that are inconsistent with those in the Option Agreement as a result of a clerical error in the papering of the Option Agreement,
the corporate records will control and you will have no legally binding right to the incorrect term in the Option Agreement.

 

(c)              
Stockholder Rights. You will not be deemed
to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to your option
unless and until (i) you have satisfied all requirements for exercise of, or the issuance of shares of Common Stock under,
your option pursuant to its terms, and (ii) the issuance of the Common Stock subject to your option has been entered into
the books and records of the Company.

 

(d)             
Change in Time Commitment. In the event your
regular level of time commitment in the performance of your services for the Company and any Affiliates is reduced (for example,
and without limitation, if you are an Employee of the Company and you have a change in status from a full-time Employee to a part-time
Employee) after the Date of Grant, the Board has the right in its sole discretion to (x) make a corresponding reduction in the
number of shares subject to any portion of such option that is scheduled to vest or become payable after the date of such change
in time commitment, and (y) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable
to such option. In the event of any such reduction, you will have no right with respect to any portion of your option that is so
reduced or extended.

 

(e)              
Investment Assurances. The Company may require
you, as a condition of exercising your option, (i) to give written assurances satisfactory to the Company as to your knowledge
and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company
who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together
with the purchaser representative, the merits and risks of exercising your option; and (ii) to give written assurances satisfactory
to the Company stating that you are acquiring Common Stock subject to your option for your own account and not with any present
intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant
to such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or acquisition of Common Stock
under your option has been registered under a then currently effective registration statement under the Securities Act, or (B) as
to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the
circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends
on stock certificates issued under the Option Agreement as such counsel deems necessary or appropriate in order to comply with
applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.

 

 

 

 

 

 

 

    	 	9	 

     

    

 

(f)               
Clawback/Recovery. This option will be subject
to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of
any national securities exchange or association on which the Company’s securities are listed or as is otherwise required
by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. No recovery of compensation under such
a clawback policy will be an event giving rise to a right to resign for “good reason” or “constructive termination”
(or similar term) under any agreement with the Company. 

 

17.             
Choice of Law. The
laws of the Company’s state of incorporation will govern all questions concerning the construction, validity and interpretation
of your option, without regard to that state’s conflict of laws rules.

 

18.             
Definitions. As
used in the Option Agreement, the following definitions will apply to the capitalized terms indicated below: 

 

(a)              
“Affiliate” means, at the time of determination, any “parent”
or “majority-owned subsidiary” of the Company, as such terms are defined in Rule 405 promulgated under the Securities
Act. The Board will have the authority to determine the time or times at which “parent” or “majority-owned subsidiary”
status is determined within the foregoing definition. 

 

(b)             
“Board” means the Board of Directors of the Company.

 

(c)              
“Capitalization Adjustment” means any change that is made in,
or other events that occur with respect to, the Common Stock subject to your option after the Date of Grant without the receipt
of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend,
dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend,
combination of shares, exchange of shares, change in corporate structure, or any similar equity restructuring transaction, as that
term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor
thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization
Adjustment.

 

(d)             
“Cause” will have the meaning ascribed to such term in any written
agreement between you and the Company defining such term and, in the absence of such agreement, such term means, with respect to
you, the occurrence of any of the following events: (i) your commission of any felony or any crime involving fraud, dishonesty
or moral turpitude under the laws of the United States or any state thereof; (ii) your attempted commission of, or participation
in, a fraud or act of dishonesty against the Company; (iii) your intentional, material violation of any contract or agreement
between you and the Company or of any statutory duty owed to the Company; (iv) your unauthorized use or disclosure of the
Company’s confidential information or trade secrets; or (v) your gross misconduct. The determination that a termination
of your Continuous Service is either for Cause or without Cause will be made by the Company, in its sole discretion. Any determination
by the Company that your Continuous Service was terminated with or without Cause for the purposes of your option will have no effect
upon any determination of the rights or obligations of the Company or you for any other purpose.

 

(e)              
“Code” means the Internal Revenue Code of 1986, as amended,
including any applicable regulations and guidance thereunder.

 

(f)               
“Committee” means a committee of one or more Directors to whom
authority has been delegated by the Board in accordance with Section 14(c).

 

(g)              
“Common Stock” means the common stock of the Company.

 

(h)             
“Company” means Xenetic Biosciences, Inc., a Nevada corporation.

 

 

 

 

 

 

 

    	 	10	 

     

    

 

(i)                
“Consultant” means any person, including an advisor, who is
(i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services,
or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service
solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a “Consultant”
for purposes of your option.

 

(j)               
“Continuous Service” means that your service with the Company
or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in
which you render service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the entity for which
you render such service, provided that there is no interruption or termination of your service with the Company or an Affiliate,
will not terminate your Continuous Service; provided, however, that if the entity for which you are rendering services ceases
to qualify as an Affiliate, as determined by the Board in its sole discretion, your Continuous Service will be considered to have
terminated on the date such entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the Company
to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted
by law, the Board or the chief executive officer of the Company, in that party’s sole discretion, may determine whether Continuous
Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer,
including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their
successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in
your option only to such extent as may be provided in the Company’s leave of absence policy, in the written terms of any
leave of absence agreement or policy applicable to you, or as otherwise required by law.

 

(k)             
“Change in Control” means the occurrence, in a single transaction
or in a series of related transactions, of any one or more of the following events: 

 

(i)                
any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the
Company representing more than fifty percent (50%) of the combined voting power of the Company’s then outstanding securities
other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall
not be deemed to occur (A) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or
any other Exchange Act Person from the Company in a transaction or series of related transactions the primary purpose of which
is to obtain financing for the Company through the issuance of equity securities or (B) solely because the level of Ownership held
by any Exchange Act Person (the “Subject Person”) exceeds the designated percentage threshold of the
outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the
number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result
of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner
of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage
of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in
Control shall be deemed to occur; 

 

(ii)             
there is consummated a merger, consolidation or similar transaction involving (directly
or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders
of the Company immediately prior thereto do not Own, directly or indirectly, either (A) outstanding voting securities representing
more than fifty percent (50%) of the combined outstanding voting power of the surviving Entity in such merger, consolidation or
similar transaction or (B) more than fifty percent (50%) of the combined outstanding voting power of the parent of the surviving
Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership
of the outstanding voting securities of the Company immediately prior to such transaction;

 

 

 

    	 	11	 

     

    

(iii)           
there is consummated a sale, lease, exclusive license or other disposition of all or substantially
all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all
or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than fifty percent (50%)
of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same
proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license
or other disposition; or 

 

(iv)            
individuals who, on the Date of Grant, are members of the Board (the “Incumbent
Board”) cease for any reason to constitute at least a majority of the members of the Board; provided, however,
that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority
vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this definition, be considered
as a member of the Incumbent Board. 

 

For clarity, the term
Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing
the domicile of the Company.

 

(l)                
 “Director” means a member of the Board.

 

(m)           
“Disability” means, your inability to engage in any substantial
gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death
or that has lasted or can be expected to last for a continuous period of not less than twelve (12) months as provided
in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence
as the Board deems warranted under the circumstances.

 

(n)             
 “Employee” means any person employed by the Company or an Affiliate.
However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee”
for purposes of your option.

 

(o)              
“Entity” means a corporation, partnership, limited liability
company or other entity.

 

(p)             
“Exchange Act” means the Securities Exchange Act of 1934, as
amended.

 

(q)             
“Exchange Act Person” means any natural person, Entity or “group”
(within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person”
shall not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary
of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary
of the Company, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, (iv) an Entity
Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock
of the Company; or (v) any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange
Act) that, as of the Date of Grant, is the Owner, directly or indirectly, of securities of the Company representing more than fifty
percent (50%) of the combined voting power of the Company’s then outstanding securities.

 

(r)              
“Fair Market Value” means, as of any date, the value of the
Common Stock determined by the Board in compliance with Section 409A of the Code.

 

 

 

 

 

 

 

 

    	 	12	 

     

    

 

(s)               
“Own,” “Owned,” “Owner,”
“Ownership” A person or Entity shall be deemed to “Own,” to have “Owned,” to
be the “Owner” of, or to have acquired “Ownership” of securities if such person or Entity, directly or
indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes
the power to vote or to direct the voting, with respect to such securities.

 

(t)               
“Securities Act” means the Securities Act of 1933, as amended.

 

(u)             
“Subsidiary” means, with respect to the Company, (i) any
corporation of which more than fifty percent (50%) of the outstanding capital stock having ordinary voting power to elect
a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes
of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly
or indirectly, owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company
has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than
fifty percent (50%).

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	13	 

     

    

 

Attachment II

 

Notice
of Exercise

 

	Xenetic Biosciences, Inc.	 	 
	[Address]	 	 
	[City
and State]	 	Date of Exercise: _______________

 

This constitutes notice
to Xenetic Biosciences, Inc. (the “Company”) under my stock option that I elect to purchase the below
number of shares of Common Stock of the Company (the “Shares”) for the price set forth below.

 

	 	Type of option (check one):	Nonstatutory
	 	 	 
	 	Stock option dated:	_______________
	 	 	 
	 	Number of Shares as

to which option is

exercised:	_______________
	 	 	 
	 	Certificates to be

issued in name of:	_______________
	 	 	 
	 	Total exercise price:	$______________
	 	 	 
	 	Cash payment delivered

herewith:	$______________
	 	 	 
	 	Value of ________ Shares delivered herewith:	$______________
	 	 	 
	 	Regulation T Program (cashless exercise):	$______________

 

By this exercise, I
agree (i) to provide such additional documents as you may require pursuant to the terms of the Notice of Grant and Option
Agreement and (ii) to provide for the payment by me to you (in the manner designated by you) of your withholding obligation,
if any, relating to the exercise of this option.

 

Very truly yours,

 

____________________________________

Signature

 

____________________________________

Print Name

 

 

 

 

 

 

 

 

 

 

 

    	 	14Exhibit

Exhibit 4.3

SECOND SUPPLEMENTAL INDENTURE  
 
BETWEEN  
 
EXELON CORPORATION  
 
AND
THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., 
AS TRUSTEE

DATED AS OF APRIL 3, 2017
3.497% JUNIOR SUBORDINATED NOTES DUE 2022
(formerly designated 2.50% Junior Subordinated Notes due 2024)

TABLE OF CONTENTS

	
		
	Page

	Article I RELATION TO INDENTURE; ADDITIONAL DEFINITIONS
	2

	1.1     Relation to Indenture
	2

	1.2     Additional Definitions
	2

	Article II GENERAL TERMS AND CONDITIONS OF THE ORIGINAL NOTES 
	3

	2.1     Designation and Principal Amount
	3

	2.2     Modified Terms
	4

	2.3     Amendment of the First Supplemental Indenture
	4

	Article III FORM OF JUNIOR SUBORDINATED NOTE
	6

	3.1     Form of Junior Subordinated Note
	6

	Article IV MISCELLANEOUS
	6

	4.1     Ratification of Indenture; Second Supplemental Indenture Controls
	6

	4.2     Recitals
	6

	4.3     Governing Law
	7

	4.4     Separability
	7

	4.5     Counterparts
	7

i

SECOND SUPPLEMENTAL INDENTURE
THIS SECOND SUPPLEMENTAL INDENTURE, dated as of April 3, 2017 (the “Second Supplemental Indenture”), is between EXELON CORPORATION, a Pennsylvania corporation, having its principal office at 10 South Dearborn Street, Chicago, Illinois 60603 (the “Company”), and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as trustee of the Securities established by the First Supplemental Indenture (hereinafter defined), having a corporate trust office at 2 North LaSalle Street, Suite 1020, Chicago, Illinois 60602 (herein called the “Trustee”). 
WHEREAS, the Company has heretofore entered into an Indenture (For Unsecured Subordinated Debt Securities), dated as of June 17, 2014, between the Company and the Trustee (the “Base Indenture”);
WHEREAS, the Base Indenture is incorporated herein by this reference and the Base Indenture, as supplemented and amended by the First Supplemental Indenture, dated as of June 17, 2014, between the Company and the Trustee (the “First Supplemental Indenture”), as supplemented and amended by this Second Supplemental Indenture, and as may be hereafter supplemented or amended from time to time in accordance herewith and therewith, is herein referred to as the “Indenture”;
WHEREAS, under the Base Indenture, a new series of Securities may at any time be established in accordance with the provisions of the Base Indenture and the terms of such series may be described by a supplemental indenture executed by the Company and the Trustee;
WHEREAS, pursuant to the Base Indenture, as supplemented and amended by the First Supplemental Indenture, the Company created a new series of Securities designated as the 2.50% Junior Subordinated Notes due 2024 (the “Original Notes”) and appointed the Trustee as Trustee under the Base Indenture with respect to such series of Securities;
WHEREAS, a Successful Remarketing of the Original Notes has been conducted pursuant to the Remarketing Agreement (as defined herein) and the Reset Rate has been established in connection with such Successful Remarketing as 3.497% per annum;
WHEREAS, (i) Section 8.01 of the First Supplemental Indenture provides that the Company and the Trustee may enter into a supplemental indenture to the Base Indenture without the consent of the holders of the Original Notes to make any modification to the terms of the Original Notes permitted pursuant to Section 9.04 of the First Supplemental Indenture in connection with a Remarketing that is made in accordance with the terms of the Indenture and (ii) Section 1201 of the Base Indenture provides that the Company and the Trustee may make any changes permitted by a supplemental indenture without the consent of the holders of the Original Notes provided such changes only affect the tranche of securities to which such supplemental indenture applies;
WHEREAS, Section 1201 of the Base Indenture provides that the Company and the Trustee may enter into a supplemental indenture to the Base Indenture without the consent of the holders of the Original Notes to change or eliminate any provision of the Indenture or to add any new provision to the Indenture and Section 8.01 of the First Supplemental Indenture provides that the 

1

Company and the Trustee may enter into a supplemental indenture to the Base Indenture without the consent of the holders of the Original Notes to make provision in regard to matters arising under the Base Indenture, in each case, provided, that such change, elimination, addition or provision, as applicable, shall not adversely affect the interest of the holders of Securities of any series in any material respect;
WHEREAS, the Company has requested that the Trustee execute and deliver this Second Supplemental Indenture, and all requirements necessary to make this Second Supplemental Indenture a valid instrument in accordance with its terms, have been performed, and the execution and delivery of this Second Supplemental Indenture has been duly authorized in all respects;
NOW, THEREFORE, in consideration of the covenants and agreements set forth herein and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

ARTICLE I
RELATION TO INDENTURE; ADDITIONAL DEFINITIONS

1.1    Relation to Indenture. This Second Supplemental Indenture constitutes an integral part of the Base Indenture, and supplements and amends the Base Indenture, as supplemented and amended by the First Supplemental Indenture, solely with respect to the Original Notes. To the extent of any inconsistency between this Second Supplemental Indenture and the Base Indenture or the First Supplemental Indenture, this Second Supplemental Indenture shall govern.

1.2    Additional Definitions. For all purposes of this Second Supplemental Indenture, except as otherwise expressly provided or unless the context otherwise requires:
(a)    the capitalized terms not otherwise defined herein shall have the meanings set forth in the Base Indenture as supplemented and amended by the First Supplemental Indenture, or, if not defined in the Base Indenture, as supplemented and amended by the First Supplemental Indenture, in the Purchase Contract and Pledge Agreement;
(b)    the terms defined in this Article have the meanings assigned to them in this Article and include the plural as well as the singular;
(c)    all other terms used herein which are defined in the Trust Indenture Act of 1939, as amended, whether directly or by reference therein, have the meanings assigned to them therein;
(d)    a reference to a Section or Article is to a Section or Article of this Second Supplemental Indenture unless otherwise stated;
(e)    the words “herein,” “hereof” and “hereunder” and other words of similar import refer to this Second Supplemental Indenture as a whole and not to any particular Article, Section or other subdivision;

2

(f)    headings are for convenience of reference only and do not affect interpretation;
“Junior Subordinated Notes” shall have the meaning specified in SECTION 2.1.
“Remarketed Notes” means, with respect to the 2017 Successful Remarketing, the $1,150,000,000 aggregate principal amount of Original Notes underlying the Pledged Applicable Ownership Interests in Notes as identified to the Remarketing Agents by the Purchase Contract Agent pursuant to the terms of the Purchase Contract and Pledge Agreement. There were no Separate Notes subject to the Remarketing.
“Remarketing Agents” means Citigroup Global Markets Inc., Goldman, Sachs & Co. and Merrill Lynch, Pierce, Fenner & Smith Incorporated, Credit Agricole Securities (USA) Inc., Credit Suisse Securities (USA) LLC, PNC Capital Markets LLC, Loop Capital Markets LLC, Lebenthal & Co., LLC and Mischler Financial Group, Inc., the Remarketing Agents appointed by the Company, pursuant to the Remarketing Agreement.
“Remarketing Agreement” means the Remarketing Agreement, dated as of February 8, 2017, by and among the Company, the Purchase Contract Agent, as attorney-in-fact of the holders of the Purchase Contracts, the Remarketing Agents, as the reset agents and the remarketing agents, and the Quotation Agent for the remarketing of $1,150,000,000 aggregate principal amount of the Original Notes, as supplemented and amended by the Joinder thereto dated as of March 29, 2017. 
“2017 Successful Remarketing” means the Successful Remarketing conducted by the Remarketing Agents pursuant to the Remarketing Agreement, with a Remarketing Settlement Date of even date herewith.
The terms “Company,” “Trustee,” “Base Indenture,” “First Supplemental Indenture,” and “Indenture” shall have the respective meanings set forth in the recitals to this Second Supplemental Indenture.

ARTICLE II
GENERAL TERMS AND CONDITIONS OF THE ORIGINAL NOTES

2.1    Designation and Principal Amount. The Original Notes are hereby re-designated as a series of Securities to be known as the 3.497% Junior Subordinated Notes due 2022 (the “Junior Subordinated Notes”), with such series limited in principal amount to $1,150,000,000; provided, however, that the Company, without notice to or consent of the Holders of the Junior Subordinated Notes, may issue additional Junior Subordinated Notes and thereby increase such principal amount in the future, on the same terms and conditions (except for issue date, public offering price and, if applicable, the date from which interest accrues and the first Interest Payment Date) and with the same CUSIP number as the Junior Subordinated Notes. The Junior Subordinated Notes may be issued from time to time upon written order of the Company for the authentication and delivery of Securities pursuant to Section 303 of the Base Indenture. All references to the Original Notes in the First Supplemental Indenture, the form of Original Note attached as Exhibit A thereto and each 

3

outstanding Original Note, including, without limitation, the reference to the Original Notes in Section 2.07 of the First Supplemental Indenture as such Section 2.07 is amended hereby, shall be deemed to be references to the Junior Subordinated Notes following the re-designation effected by this Second Supplemental Indenture. 

2.2    Modified Terms. The parties hereto acknowledge that as a result of the 2017 Successful Remarketing, the terms of the Junior Subordinated Notes are, effective as of the date hereof, the modified terms pursuant to Section 9.04 of the First Supplemental Indenture and that the Reset Rate is 3.497%. Unless a Redemption occurs prior to the Maturity Date (as defined below), the Junior Subordinated Notes will mature on June 1, 2022 (the “Maturity Date”). Interest on the Junior Subordinated Notes will be payable semi-annually in arrears on June 1 and December 1. The first interest payment following this remarketing will be made on June 1, 2017 and will include interest accrued (i) at an annual rate of 2.50% from, and including, March 1, 2017 to, but excluding, April 3, 2017 and (ii) at an annual rate of 3.497% from, and including, April 3, 2017 to, but excluding, June 1, 2017. On and after April 3, 2017, the Junior Subordinated Notes will bear interest at 3.497% per year to, but excluding, the Maturity Date. 

2.3    Amendment of the First Supplemental Indenture. 
(i)    Section 2.07 of the First Supplemental Indenture is hereby amended by deleting the introductory phrase “Prior to the Purchase Contract Settlement Date.” As so amended, Section 2.07 shall state: “The provisions of Section 701 of the Base Indenture shall not apply to the Notes.” The corresponding statement on the Reverse of Note included in the Form of Original Note attached to the First Supplemental Indenture as Exhibit A and in each outstanding Original Note is also so amended hereby.
(ii)    Section 3.01 of the First Supplemental Indenture is hereby deleted in its entirety and replaced with the following:
“Section 3.01    Optional Redemption by Company. 
On and after May 1, 2022, the Notes may be redeemed, at the Company’s option, in whole or in part, at any time or from time to time, at a price per Note equal to the Redemption Price, payable on the date of Redemption (such date, the “Redemption Date”). 
At the Company’s request, the Trustee will give the notice of redemption in the Company’s name and at its expense; provided, however, that the Company will have delivered to the Trustee at least 18 days prior to the Redemption Date (or such shorter period as the Trustee may agree), an Officer’s Certificate requesting that the Trustee give such notice and setting forth the information to be stated in such notice as provided in Section 3.03 hereof. 
Any Redemption or notice of any redemption may, at the Company’s discretion, be subject to one or more conditions precedent, including, but not limited to, completion of an equity offering, other offering, issuance of indebtedness or other transaction or event. Notice of any redemption in respect thereof may be given prior to the completion thereof and may be partial as a result of only some of the conditions being satisfied.

4

If such Redemption or notice is subject to satisfaction of one or more conditions precedent, such notice shall state that, in the Company’s discretion, the Redemption Date may be delayed until such time as any or all such conditions shall be satisfied (or waived by the Company in its sole discretion), or such Redemption may not occur and such notice may be rescinded in the event that any or all such conditions shall not have been satisfied (or waived by the Company in its sole discretion) by the Redemption Date, or by the Redemption Date so delayed.
If less than all of the Notes are to be redeemed at any time, the Trustee will select the Notes for Redemption on a pro rata basis (or as nearly as practicable) if the Notes are represented by physical certificates or by lot or such other similar method in accordance with the procedures of the Depository if the Notes are presented by global certificates.” 
(iii)    Section 3.03 of the First Supplemental Indenture is hereby deleted in its entirety and replaced with the following:
“Section 3.03    Notice of Redemption.   Notice of any Redemption pursuant to this Article III will be mailed or electronically delivered not less than 15 days and not more than 60 days before the Redemption Date to each Holder of Notes to be redeemed at such Holder’s registered address or otherwise in accordance with the procedures of the Depository and such notice of Redemption shall at least specify, subject to any other requirements in Article Four of the Base Indenture:
(a)    the Redemption Date;
(b)    the Redemption Price;
(c)    that, on the Redemption Date, the Redemption Price shall become due and payable upon each of the Notes to be redeemed and that such Notes shall cease to accrue interest on and after the Redemption Date, unless there is a default in payment of the Redemption Price; and
(d)     if such Redemption or notice is subject to satisfaction of one or more conditions precedent, such notice shall state that, in the Company’s discretion, the Redemption Date may be delayed until such time as any or all such conditions shall be satisfied (or waived by the Company in its sole discretion), or such Redemption may not occur and such notice may be rescinded in the event that any or all such conditions shall not have been satisfied (or waived by the Company in its sole discretion) by the Redemption Date, or by the Redemption Date so delayed.”
(iv)    Section 3.04 of the First Supplemental Indenture is hereby deleted in its entirety and replaced with the following:
“Section 3.04    Amendments to Article Four of Base Indenture.  Solely for purposes of the Notes, “45 days” in Section 402 of the Base Indenture shall be amended to state “15 days.””

5

(v)    Section 8.01(i) of the First Supplemental Indenture is hereby deleted in its entirety and replaced with the following:
“to amend the Notes, the Base Indenture (insofar as it relates to the Notes) and the Indenture to conform the provisions thereof or hereof to the descriptions thereof or hereof contained in the preliminary prospectus supplement dated March 29, 2017 for the Junior Subordinated Notes, as supplemented by any free writing prospectus used in connection with the offering of the Junior Subordinated Notes, under the section entitled “Description of the Junior Subordinated Notes,” and the preliminary prospectus supplement dated June 10, 2014 for the Equity Units, as supplemented by any free writing prospectus used in connection with the offering of the Equity Units, under the sections entitled “Description of the Equity Units,” “Description of the Purchase Contracts,” “Certain Provisions of the Purchase Contract and Pledge Agreement” and “Description of the Junior Subordinated Notes.””

ARTICLE III
FORM OF JUNIOR SUBORDINATED NOTE

3.1    Form of Junior Subordinated Note. The Junior Subordinated Notes and the Trustee’s Certificate of Authentication to be endorsed thereon are to be substantially in the form attached to the First Supplemental Indenture as Exhibit A except that designation of the Securities set forth on such form may, but need not, be revised to refer to the new designation and modified terms of the Junior Subordinated Notes provided for in SECTIONS 2.1, 2.2 and 2.3, respectively, hereof and the Reverse of Note may, but need not, be revised to delete the phrase “Prior to the Purchase Contract Settlement Date” preceding the statement that “the provisions of Section 701 of the Base Indenture shall not apply to the Notes.” For the avoidance of doubt, it shall not be necessary for previously issued and authenticated Securities to be replaced as a result of the re-designation of the Original Notes and the amendments provided for in SECTION 2.3 hereof, but such revisions shall in all events be applicable to such previously issued and authenticated Securities.

ARTICLE IV
MISCELLANEOUS

4.1    Ratification of Indenture; Second Supplemental Indenture Controls. The Base Indenture, as supplemented and (solely for purposes of the Original Notes) amended by the First Supplemental Indenture, as supplemented and amended by this Second Supplemental Indenture, is in all respects ratified and confirmed, and this Second Supplemental Indenture shall be deemed part of the Base Indenture, as supplemented and amended by the First Supplemental Indenture, in the manner and to the extent herein and therein provided. The provisions of this Second Supplemental Indenture shall supersede the provisions of the Base Indenture, as supplemented and amended by the First Supplemental Indenture, to the extent the Base Indenture, as supplemented and amended by the First Supplemental Indenture, is inconsistent herewith.

4.2    Recitals. The recitals herein contained are made by the Company only and not by the Trustee, and the Trustee does not assume any responsibility for the correctness thereof. The Trustee does not make any representation as to the validity or sufficiency of this Second 

6

Supplemental Indenture. All of the provisions contained in the Base Indenture, as supplemented and amended by the First Supplemental Indenture, in respect of the rights, powers, privileges, protections, duties and immunities of the Trustee shall be applicable in respect of the Junior Subordinated Notes and of this Second Supplemental Indenture (to the extent relating to the Junior Subordinated Notes) as fully and with like effect as if set forth herein in full. 

4.3    Governing Law. This Second Supplemental Indenture and each Junior Subordinated Note shall be deemed to be a contract made under the internal laws of the State of New York, and for all purposes shall be governed by and construed in accordance with the laws of said State, without regard to the conflicts of law principles thereof.

4.4    Separability. In case any one or more of the provisions contained in this Second Supplemental Indenture or in the Junior Subordinated Notes shall for any reason be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Second Supplemental Indenture or of the Junior Subordinated Notes, but this Second Supplemental Indenture and the Junior Subordinated Notes shall be construed as if such invalid or illegal or unenforceable provision had never been contained herein or therein.  

4.5    Counterparts. This Second Supplemental Indenture may be executed in any number of counterparts each of which shall be an original; but such counterparts shall together constitute but one and the same instrument. The exchange of copies of this Second Supplemental Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this Second Supplemental Indenture as to the parties hereto and may be used in lieu of the original Second Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes.

7

IN WITNESS WHEREOF, the parties hereto have caused this Second Supplemental Indenture to be duly executed as of the date first above written.
	
			
	 
	 
	EXELON CORPORATION 

	 
	 
	 

	 
	 
	 

	 
	By:
	/s/ Francis O. Idehen

	 
	 
	Name:    Francis O. Idehen

	 
	 
	Title:    Vice President and Treasurer

     

	
			
	 
	 
	THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. 

	 
	 
	 

	 
	 
	 

	 
	By:
	/s/ R. Tarnas

	 
	 
	Name:    R. Tarnas

	 
	 
	Title:    Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}]]